HistoIndex Secures $9M for US Expansion and AI Pathology Tests

HistoIndex has secured a SGD9 million investment to support its expansion in the US, announced in a press release. The funding round was led by OCBC, marking its first investment in a medical technology company, with continued support from existing shareholders ZIG Ventures and SEEDS Capital.

The investment will focus on expanding HistoIndex-partnered laboratories and operations within the US and developing next-generation AI-powered digital pathology tests for Metabolic Dysfunction-Associated Steatohepatitis (MASH) patients. This includes the launch of FibroSIGHT™, a Laboratory Developed Test now available for order in the US, designed to provide accurate liver fibrosis assessments.

Dr. Gideon Ho, CEO of HistoIndex, stated that the investment positions the company for strategic expansion in the US and accelerates the adoption of advanced digital pathology solutions aimed at transforming MASH diagnosis and treatments.